TICKERNERD
Menu
APGEAPGEHealthcare · Biotechnology

APGE Stock Forecast: Apogee Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$134
+0.01% on the day

The 15 Wall Street analysts covering Apogee Therapeutics, Inc. hold a median 12-month price target of $135 — +0.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 45 of 100 as at 1 Aug 2026 — in the lower half.

Market cap
$10.1B
Ticker Nerd rank
45 / 100
Median analyst target
$135
Analysts covering
15
Total return, dividends reinvested
1W
−0.1%
1M
+0.9%
YTD
+77.7%
1Y
+255.3%
From 52W high
−0.1%
From 52W low
+287.0%
$35
$134
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

APGE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Apogee Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
45 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
100
Value
79
Volatility
76
Quality
50
Revisions
45
Issuance
41
Growth
36
Accruals
25
Size
16

Momentum (100): The shares have been drifting up relative to others.

Accruals (25): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (16): Larger than most of the companies we track — more scrutinised, less often mispriced.

The rank is the raw material. Whether the rules would actually own Apogee Therapeutics, Inc. — and when they’d sell — is the membership.

Wall Street

APGE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on APGE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100$120$140Oct 25Jan 26Apr 26Jul 26APGEHigh $137Median $135Low $81

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says15 analysts
3 Buy12 Hold0 Sell
Low $81Median $135High $137

The green dot is the last close — the median target sits +0.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
24 June 2026GuggenheimDowngradeNeutral—
24 June 2026MizuhoDowngradeNeutral$110 → $135
24 June 2026StifelDowngradeHold$133 → $135
24 June 2026TD CowenDowngradeHold—
23 June 2026CitigroupDowngradeNeutral$125 → $135
23 June 2026Deutsche BankDowngradeHold$116 → $135
23 June 2026RBC CapitalMaintainsSector Perform$97 → $135
23 June 2026UBSDowngradeNeutral$100 → $135
23 June 2026WedbushDowngradeNeutral$135
22 June 2026Canaccord GenuityDowngradeHold$130 → $135
8 June 2026RBC CapitalMaintainsSector Perform—
27 May 2026BTIGReiteratesBuy—
27 May 2026Truist SecuritiesMaintainsHold—
27 May 2026WedbushMaintainsOutperform—
1 May 2026Rothschild & CoInitiatesBuy—
30 Mar 2026MizuhoMaintainsOutperform—
24 Mar 2026Canaccord GenuityMaintainsBuy—
24 Mar 2026CitigroupMaintainsBuy—
24 Mar 2026GuggenheimMaintainsBuy—
23 Mar 2026BTIGReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

APGE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
0
Fundamentals

Apogee Therapeutics, Inc. (APGE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−35.8×

Cheaper than 97% of US stocks

Price / sales
—
Price / book
7.9×

Cheaper than 13% of US stocks

EV / EBITDA
−29.6×

Cheaper than 91% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−28.5%

Higher than 28% of US stocks

Return on assets
−19.0%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

APGE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
APGEApogee Therapeutics, Inc.$10.1B
45
KRYSKrystal Biotech, Inc.$10.1B
73
SMMTSummit Therapeutics, Inc.$10.4B
18
HALOHalozyme Therapeutics, Inc.$9.8B
85
NUVLNuvalent, Inc.$9.7B
—
CYTKCytokinetics, Inc.$9.6B
74
MDGLMadrigal Pharmaceuticals, Inc.$10.7B
67
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. APGE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest APGE news & analysis

Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE

Business Wire · 30 July 2026negative

Kahn Swick & Foti, LLC is investigating the proposed sale of Apogee Therapeutics to AbbVie, under which shareholders would receive $135.11 per share, to assess whether the consideration and sale process are adequate.

Why it matters — APGE shareholders should be aware that a law firm is scrutinizing the fairness of the sale price and process, which could affect the outcome of the proposed acquisition.

Is Apogee Therapeutics Inc. (APGE) Stock Outpacing Its Medical Peers This Year?

Zacks Investment Research · 28 July 2026neutral

A Zacks Investment Research article compares the year-to-date stock performance of Apogee Therapeutics (APGE) against Iovance Biotherapeutics (IOVA) and the broader medical sector.

Why it matters — This comparison gives APGE investors context on how the stock is tracking relative to a peer and the sector overall year-to-date.

FAQ

Frequently asked questions about APGE stock

What is the APGE stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Apogee Therapeutics, Inc. have a median 12-month price target of $135, with estimates ranging from $81 to $137. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is APGE stock a buy right now?

Of the 15 analysts covering Apogee Therapeutics, Inc., 3 rate it a Buy, 12 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Apogee Therapeutics, Inc. 45 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank APGE?

As at 1 Aug 2026, Apogee Therapeutics, Inc. ranks 45 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).

Will APGE stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +0.7% from the last close, and Ticker Nerd's factor model ranks Apogee Therapeutics, Inc. 45 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the APGE stock forecast for 2030?

No analyst covering Apogee Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APGE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $81 to $137 over the next 12 months.

How has APGE stock performed over the past year?

Apogee Therapeutics, Inc. returned +255.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Apogee Therapeutics, Inc. do?

Apogee Therapeutics Inc. is a clinical-stage biotechnology company focused on developing biologic medicines for immunological and inflammatory diseases.

What is the latest news on APGE?

The most recent item we track (Business Wire, 30 July 2026): "Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE". Kahn Swick & Foti, LLC is investigating the proposed sale of Apogee Therapeutics to AbbVie, under which shareholders would receive $135.11 per share, to assess whether the consideration and sale process are adequate.

Company

About Apogee Therapeutics, Inc.

Apogee Therapeutics Inc. is a clinical-stage biotechnology company focused on developing biologic medicines for immunological and inflammatory diseases. Headquartered in Waltham, Massachusetts and founded in 2022, the company concentrates on validated immunology targets and applies advanced antibody engineering to optimize half-life, dosing convenience, and overall therapeutic profile. Its lead program, zumilokibart (formerly APG777), is a monoclonal antibody targeting IL-13, initially developed for atopic dermatitis and also being evaluated in asthma and eosinophilic esophagitis. Beyond this flagship candidate, Apogee is building a diversified pipeline of novel antibodies and combinations, such as APG273, directed at key inflammatory pathways relevant to dermatologic, respiratory, and gastroenterological conditions including asthma, chronic obstructive pulmonary disease, and other type 2 inflammatory disorders. Operating as a single reportable segment centered on research and development, Apogee collaborates with global clinical and manufacturing partners, aiming to bring differentiated biologic options to large, underserved inflammatory and immunology markets.

CEO Dr. Michael Thomas Henderson M.D. · 261 employees · United States · https://www.apogeetherapeutics.com